<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        127-124-19
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        TYRA 10 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TADALAFIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        28.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="DAR ALDAWA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            DAR ALDAWA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            DAR ALDAWA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G04BE08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Tyra<sup>&reg;</sup></strong> is a treatment for adult men with erectile dysfunction. This is when a man cannot get, or keep a hard, erect penis suitable for sexual activity. <strong>Tyra<sup>&reg;</sup></strong> has been shown to significantly improve the ability of obtaining a hard erect penis suitable for sexual activity.</p><p><strong>Tyra<sup>&reg;</sup></strong> contains the active substance tadalafil which belongs to a group of medicines called phosphodiesterase type 5 inhibitors. Following sexual stimulation <strong>Tyra<sup>&reg;</sup></strong> works by helping the blood vessels in your penis to relax, allowing the flow of blood into your penis. The result of this is improved erectile function. <strong>Tyra<sup>&reg;</sup></strong> will not help you if you do not have erectile dysfunction.</p><p>It is important to note that <strong>Tyra<sup>&reg;</sup></strong> does not work if there is no sexual stimulation. You and your partner will need to engage in foreplay, just as you would if you were not taking a medicine for erectile dysfunction.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Tyra<sup>&reg;</sup> tablets if you:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp; are allergic to tadalafil or any of the other ingredients of this medicine.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; are taking any form of organic nitrate or nitric oxide donors such as amyl nitrite. This is a group of medicines (&ldquo;nitrates&rdquo;) used in the treatment of angina pectoris (&ldquo;chest pain&rdquo;). Tadalafil has been shown to increase the effects of these medicines. If you are taking any form of nitrate or are unsure tell your doctor.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; have serious heart disease or recently had a heart attack within the last 90 days.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; recently had a stroke within the last 6 months.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; have low blood pressure or uncontrolled high blood pressure.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; ever had loss of vision because of non-arteritic anterior ischemic optic neuropathy (NAION), a condition described as &ldquo;stroke of the eye&rdquo;.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; are taking riociguat. This drug is used to treat pulmonary arterial hypertension (i.e., high blood pressure in the lungs) and chronic thromboembolic pulmonary hypertension (i.e., high blood pressure in the lungs secondary to blood clots). PDE5 inhibitors, such as tadalafil, have been shown to increase the hypotensive effects of this medicine. If you are taking riociguat or are unsure tell your doctor.</p><p>&nbsp;</p><p><strong>Take special care with Tyra<sup>&reg;</sup> </strong></p><p>Talk to your doctor before taking <strong>Tyra<sup>&reg;</sup></strong>.</p><p>Be aware that sexual activity carries a possible risk to patients with heart disease because it puts an extra strain on your heart. If you have a heart problem you should tell your doctor.</p><p>Before taking the tablets, tell your doctor if you have:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; sickle cell anaemia (an abnormality of red blood cells).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; multiple myeloma (cancer of the bone marrow).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; leukaemia (cancer of the blood cells).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; any deformation of your penis.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; a serious liver problem.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; a severe kidney problem.</p><p>It is not known if <strong>Tyra<sup>&reg;</sup></strong> is effective in patients who have had:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; pelvic surgery.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; removal of all or part of the prostate gland in which nerves of the prostate are cut (radical non-nerve-sparing prostatectomy).</p><p>If you experience sudden decrease or loss of vision, stop taking <strong>Tyra<sup>&reg;</sup></strong> and contact your doctor immediately.</p><p>Decreased or sudden hearing loss has been noted in some patients taking tadalafil. Although it is not known if the event is directly related to tadalafil, if you experience decreased or sudden hearing loss, stop taking <strong>Tyra<sup>&reg;</sup></strong> and contact your doctor immediately.</p><p><strong>Tyra<sup>&reg;</sup></strong> is not intended for use by women.</p><p><strong>Children and adolescents</strong></p><p><strong>Tyra<sup>&reg;</sup></strong> is not intended for use by children and adolescents under the age of 18.</p><p>&nbsp;</p><p><strong>Taking other medicines, herbal or dietary supplements</strong></p><p>Tell your doctor if you are taking, have recently taken or might take any other medicines.</p><p>Do not take <strong>Tyra<sup>&reg;</sup></strong> if you are already taking nitrates.</p><p>Some medicines may be affected by <strong>Tyra<sup>&reg;</sup></strong> or they may affect how well <strong>Tyra<sup>&reg;</sup></strong> will work. Tell your doctor or pharmacist if you are already taking:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; an alpha blocker (used to treat high blood pressure or urinary symptoms associated with benign prostatic hyperplasia).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; other medicines to treat high blood pressure.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; riociguat.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; a 5- alpha reductase inhibitor (used to treat benign prostatic hyperplasia).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; medicines such as ketoconazole tablets (to treat fungal infections) and protease inhibitors for treatment of AIDS or HIV infection.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; phenobarbital, phenytoin and carbamazepine (anticonvulsant medicines).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; rifampicin, erythromycin, clarithromycin or itraconazole.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; other treatments for erectile dysfunction.</p><p>&nbsp;</p><p><strong>Taking Tyra<sup>&reg;</sup> with food and drink</strong></p><p>Information on the effect of alcohol is in section 3. Grapefruit juice may affect how well <strong>Tyra<sup>&reg;</sup></strong> will work and should be taken with caution. Talk to your doctor for further information.</p><p>&nbsp;</p><p><strong>Fertility</strong></p><p>A reduction in sperm was seen in some men. These effects are unlikely to lead to a lack of fertility.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Some men taking tadalafil reported dizziness. Check carefully how you react to the tablets before driving or using machines.</p><p>&nbsp;</p><p><strong>Important information about some of the ingredients of </strong><strong>Tyra<sup>&reg;</sup> tablets</strong><strong> </strong></p><p><strong>Tyra<sup>&reg;</sup></strong> tablets contain lactose, if you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p><strong>Tyra<sup>&reg;</sup></strong> tablets are for oral use in men only. Swallow the tablet whole with some water. The tablets can be taken with or without food.</p><p><strong>The recommended starting dose</strong> is one 10 mg tablet before sexual activity. However, you have been given the dose of one 20 mg tablet as your doctor has decided that the recommended dose of 10 mg is too weak.</p><p>You may take a <strong>Tyra<sup>&reg;</sup></strong> tablet at least 30 minutes before sexual activity.</p><p><strong>Tyra<sup>&reg;</sup></strong> may still be effective up to 36 hours after taking the tablet.</p><p>Do not take <strong>Tyra<sup>&reg;</sup></strong> more than once a day. Tadalafil 10 mg and 20 mg is intended for use prior to anticipated sexual activity and is not recommended for continuous daily use.</p><p>It is important to note that <strong>Tyra<sup>&reg;</sup></strong> does not work if there is no sexual stimulation. You and your partner will need to engage in foreplay, just as you would if you were not taking a medicine for erectile dysfunction.</p><p>Drinking alcohol may affect your ability to get an erection and may temporarily lower your blood pressure. If you have taken or are planning to take <strong>Tyra<sup>&reg;</sup></strong>, avoid excessive drinking (blood alcohol level of 0.08 % or greater), since this may increase the risk of dizziness when standing up.</p><p>&nbsp;</p><p><strong>If you </strong><strong>take</strong><strong> more Tyra<sup>&reg;</sup> tablets than you should</strong></p><p>Contact your doctor. You may experience side effects described in section 4.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. These effects are normally mild to moderate in nature.</p><p><strong>If you experience any of the following side effects stop using the medicine and seek medical help immediately:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions including rashes (frequency uncommon).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; chest pain - do not use nitrates but seek immediate medical assistance (frequency uncommon).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; prolonged and possibly painful erection after taking tadalafil (frequency rare). If you have such an erection, which lasts continuously for more than 4 hours you should contact a doctor immediately.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; sudden loss of vision (frequency rare).</p><p><strong>Other side effects have been reported: </strong></p><p><strong>Common </strong>(seen in 1 to 10 in every 100 patients)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; headache, back pain, muscle aches, pain in arms and legs, facial flushing, nasal congestion, indigestion and reflux.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; <strong>Uncommon </strong>(seen in 1 to 10 in every 1,000 patients)</p><p>Dizziness, stomach ache, feeling sick, being sick (vomiting), reflux, blurred vision, eye pain, difficulty in breathing, presence of blood in urine, prolonged erection, pounding heartbeat sensation, a fast heart rate, high blood pressure, low blood pressure, nose bleeds, ringing in the ears, swelling of the hands, feet or ankles and feeling tired.</p><p><strong>Rare </strong>(seen in 1 to 10 in every 10,000 patients)</p><p>Fainting, seizures and passing memory loss, swelling of the eyelids, red eyes, sudden decrease or loss of hearing and hives (itchy red welts on the surface of the skin), penile bleeding, presence of blood in semen and increased sweating.</p><p>Heart attack and stroke have also been reported rarely in men taking tadalafil. Most of these men had known heart problems before taking this medicine.</p><p>Partial, temporary, or permanent decrease or loss of vision in one or both eyes has been rarely reported.</p><p><strong>Some additional rare side effects </strong>have been reported in men taking tadalafil. These include:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; migraine, swelling of the face, serious allergic reaction which causes swelling of the face or throat, serious skin rashes, some disorders affecting blood flow to the eyes, irregular heartbeats, angina and sudden cardiac death.</p><p>The side effects dizziness and diarrhoea have been reported more frequently in men over 75 years of age taking tadalafil<strong>.</strong></p><p><strong>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.</p><p>Do not use <strong>Tyra<sup>&reg;</sup> </strong>after the expiry date which is stated on the carton. The expiry date refers to the last day of that month.</p><p>Store below 30&deg;C in the original package.</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is tadalafil. Each tablet contains 10 or 20 mg tadalafil.</p><p><strong>Other ingredients</strong> are lactose, croscarmellose sodium, sodium laurilsulphate, hypromellose, microcrystalline cellulose, magnesium stearate, yellow iron oxide (E172), triacetin, titanium dioxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Tyra® 10 mg are yellow almond shape film coated tablet coded (C163) in one side, plain on the other side.  
Tyra® 20 mg film-coated tablets are yellow almond shaped biconvex tablets coded with (C112) on one side, plain from the other side. 
Tyra® film-coated tablets are available in packs of 4 tablets. 


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Dar Al Dawa Development &amp; Investment Co. Ltd (Na&#39;ur - Jordan).</p><p>Tel. (+962 6) 57 27 132</p><p>Fax. (+962 6) 57 27 776</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                12/2017
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">تستعمل أقراص <strong>تايرا</strong> لعلاج عدم القدرة على الإنتصاب عند الرجال. وهو حالة يعجز فيها الرجل عن بلوغ الانتصاب أو المحافظة عليه للقيام بالجماع لممارسة النشاط الجنسي. أثبت <strong>تايرا</strong> فعاليته في تحسن الإنتصاب بشكل ملحوظ والحصول على الإنتصاب المناسب لممارسة النشاط الجنسي.</p><p dir="RTL">تحتوي أقراص <strong>تايرا</strong> على المادة الفعالة تادالافيل الذي ينتمي إلى مجموعة مثبطات ثنائي إستراز الفوسفور نوع 5. بعد الحصول على التحفيز الجنسي يساعد <strong>تايرا</strong> على إسترخاء العضلات الملساء وتدفق الدم إلى أنسجة القضيب مما يؤدي إلى إنتصاب افضل. لا يعد <strong>تايرا</strong> فعالاً إذا لم يكن لديك خلل في الإنتصاب.</p><p dir="RTL">لا يحدث <strong>تايرا</strong> فعاليته في غياب التحفيز الجنسي، لذا يستلزم وجود تحفيز جنسي كما لو لم تكن تتناول <strong>تايرا</strong> .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع</strong><strong> </strong><strong>استعمال</strong><strong> </strong><strong>أقراص تايرا</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك حساسية تجاه تادالافيل أو أي من مكونات هذا الدواء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اذا كنت تتناول أي شكل من أشكال النترات العضوية أو مانحات أكسيد النيتريك مثل الأميل نتريت. تستخدم هذه المجموعة من الأدوية (&quot;النترات&quot;) في علاج الذبحة الصدرية (&quot;ألم الصدر&quot;). وقد تبين زيادة <strong>تايرا</strong> لتأثير هذه الأدوية. إذا كنت تتناول أي شكل من أشكال النترات أو حدث لديك شك أخبر طبيبك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مرض خطير في القلب أو حدث لديك مؤخرا نوبة قلبية في غضون التسعين يوما السابقة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اذا حدث لديك سكتة دماغية خلال الشهور الست السابقة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اذا كنت تعاني من إنخفاض ضغط الدم أو إرتفاع ضغط الدم غير مسيطر عليه.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اذا حدث لك فقدان للرؤية في أي وقت مضى بسبب إعتلال العصب البصري الاقفاري الأمامي اللاشرياني (NAION)، وهي حالة تم وصفها بأنها &quot;سكتة في العين&quot;.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تأخذ دواء ريوسيغات. يُستخدم هذا الدواء لعلاج ارتفاع ضغط الدم الشرياني الرئوي )أي ضغط دم مرتفع في الشرايين الرئوية) وارتفاع ضغط الدم الرئوي المزمن بسبب الانسداد التجلّطي &nbsp;)أي ضغط دم مرتفع في الشرايين الرئويّة بسبب وجود جلطات دمويّة دائمة). وقد ثبت أن مثبّطات ال PDE5 مثل تادالافيل، تزيد من المفعول المخفّض لضغط الدم لهذا الدواء. إذا كنت تأخذ دواء ريوسيغات أو إذا كنت غير متأكد، تحدّث إلى طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات</strong><strong> </strong><strong>عند</strong><strong> </strong><strong>استعمال</strong><strong> </strong><strong>أقراص تايرا</strong></p><p dir="RTL">تحدث مع طبيبك قبل تناول <strong>تايرا</strong>.</p><p dir="RTL">يجب التنبه إلى إحتمال حدوث مخاطر في المرضى الذين يعانون من أمراض القلب عند ممارسة النشاط الجنسي بسبب زيادة الإجهاد على القلب. إذا كانت لديك مشاكل في القلب يجب إخبار طبيبك.</p><p dir="RTL">أخبر طبيبك قبل تناول الأقراص إذا كان لديك:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقر الدم المنجلي (خلل في خلايا الدم الحمراء)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ورم نقوي متعدد (سرطان نخاع العظم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لوكيميا (سرطان خلايا الدم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشوه في القضيب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلة خطيرة في الكبد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلة شديدة في الكلى.</p><p dir="RTL">تعد فعالية <strong>تايرا</strong> غير معروفة في المرضى الذين قد تعرضوا ل:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جراحة في الحوض</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إزالة جزء من البروستات أو إزالة البروستات بشكل كامل عند قطع أعصاب البروستات (الجراحة الشاملة لاعصاب البروستات).</p><p dir="RTL">إذا حدث لديك إنخفاض مفاجئ أو فقدان للرؤية، توقف عن تناول <strong>تايرا</strong> وتحدث مع طبيبك على الفور.</p><p dir="RTL">لوحظ حدوث ضعف او فقدان مفاجئ في السمع في بعض المرضى الذين تناولوا تادالافيل. على الرغم انه من غير المعروف اذا كان هذا العارض مرتبط بشكل مباشر بتادالافيل، الا انه عليك وقف تناول <strong>تايرا</strong> واخبار طبيبك على الفور في حال حدوث ضعف او فقدان مفاجئ للسمع.</p><p dir="RTL">لا يستعمل <strong>تايرا</strong> من قبل النساء.</p><p dir="RTL"><strong>الأطفال والمراهقين </strong></p><p dir="RTL">لا يستعمل <strong>تايرا</strong> من قبل الأطفال والمراهقين الذين تقل أعمارهم عن 18 سنة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التداخلات</strong><strong> </strong><strong>الدوائية</strong><strong> </strong><strong>من</strong><strong> </strong><strong>أخذ</strong><strong> </strong><strong>هذا</strong><strong> </strong><strong>المستحضر</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>أدوية</strong><strong> </strong><strong>أخرى</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>أعشاب</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>مكملات</strong><strong> </strong><strong>غذائية</strong></p><p dir="RTL">أخبر طبيبك كنت تتناول أو تناولت مؤخرا أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">يمنع تناول <strong>تايرا</strong> إذا كنت تتناول النترات.</p><p dir="RTL">قد يؤثر تناول بعض الأدوية على فعالية <strong>تايرا</strong>، كما قد يؤثر <strong>تايرا</strong> على فعالية بعض الأدوية. أخبر طبيبك أو الصيدلي إذا كنت تتناول:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حاصرات ألفا (تستخدم لعلاج إرتفاع ضغط الدم أو الأعراض البولية المرتبطة بتضخم البروستات الحميد).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الأخرى التي تستخدم لعلاج إرتفاع ضغط الدم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;ريوسيغات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبط مختزلات 5-ألفا (لعلاج تضخم البروستات الحميد)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية مثل أقراص كيتوكونازول (لعلاج الإلتهابات الفطرية) ومثبطات الإنزيم البروتيني التي تستخدم لعلاج الإيدز أو فيروس نقص المناعة المكتسبة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينوباربيتال، فينيتوين وكاربامازبين (أدوية الصرع).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين، إريثروميسين، كلاريثرومايسين أو إيتراكونازول</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاجات خلل الإنتصاب الأخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول أقراص تايرا مع الطعام والشراب </strong></p><p dir="RTL">تأثير الكحول مذكور في البند 3 . قد يؤثر عصير الجريب فروت على فعالية <strong>تايرا</strong> لذا يلزم الحذر لدى تناوله. تحدث مع طبيبك للحصول على مزيد من المعلومات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الخصوبة </strong></p><p dir="RTL">لوحظ انخفاض في عدد الحيوانات المنوية لدى بعض الرجال عند تناول تادالافيل. من غير المرجح أن تؤدي هذه التأثيرات إلى نقص الخصوبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثير </strong><strong>أقراص تايرا</strong><strong> على القيادة وإستخدام الآلات</strong></p><p dir="RTL">تم الإبلاغ عن حدوث دوخة لدى بعض الرجال عند تناول تادالافيل. يجب التاكد من تأثير الدواء عليك قبل القيادة أو إستخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات </strong><strong>أقراص تايرا</strong></p><p dir="RTL">تحتوي أقراص <strong>تايرا</strong> على اللاكتوز، استشر طبيبك قبل أخذ هذا الدواء إذا أخبرك أنه ليس لديك قدرة على تحمل بعض السكريات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول الدواء تماما كما ارشدك الطبيب. في حال لم تكن متاكدا استشر طبيبك أو الصيدلي.</p><p dir="RTL">تستخدم أقراص <strong>تايرا</strong> لعلاج الرجال فقط وتؤخذ عن طريق الفم. إبتلع القرص بالكامل مع ماء. يمكن تناول الدواء مع أو بدون الطعام.</p><p dir="RTL"><strong>الجرعة الإبتدائية الإعتيادية</strong> هي 10 ملغم قبل ممارسة النشاط الجنسي. قد يزيد الطبيب الجرعة الى 20 ملغم اذا كانت فاعلية الجرعة غير كافية.</p><p dir="RTL">تستطيع تناول أقراص <strong>تايرا</strong> قبل 30 دقيقة من ممارسة النشاط الجنسي.</p><p dir="RTL">قد تستمر فعالية <strong>تايرا</strong> 36 ساعة بعد تناول<strong> </strong>الأقراص.</p><p dir="RTL">لا تتناول <strong>تايرا</strong> أكثر من مرة يوميا. تادالافيل 10 ملغم و20 ملغم مخصص ليتم تناوله قبل توقع ممارسة النشاط الجنسي ولا ينصح بتناوله بشكل يومي.</p><p dir="RTL">من المهم إدراك عدم فعالية <strong>تايرا</strong> في حال غياب التحفيز الجنسي. لذا يستلزم وجود تحفيز جنسي كما لو لم تكن تتناول <strong>تايرا</strong> .</p><p dir="RTL">قد يؤثر تناول الكحول على قدرتك على الإنتصاب ومن الممكن أن يخفض ضغط الدم لديك بشكل مؤقت. إذا تناولت أو تخطط لتناول <strong>تايرا</strong> لا تفرط في شرب الكحول (نسبة الكحول في الدم 0.08٪ أو أكثر) لأن ذلك قد يزيد من خطر حدوث دوار عند الوقوف.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة</strong><strong> </strong><strong>الزائدة</strong><strong> </strong><strong>من</strong><strong> </strong><strong>أقراص تايرا</strong></p><p dir="RTL">تحدث مع طبيبك أو الصيدلي. قد تحدث لديك التأثيرات الجانبية المذكورة في القسم 4.</p><p dir="RTL">إذا كانت لديك أي أسئلة تتعلق بإستخدام الدواء تحدث مع طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شأنه شأن الأدوية الأخرى من الممكن أن يسبب هذا الدواء تأثيرات جانبية، على الرغم من عدم حدوثها لدى جميع المرضى.</p><p dir="RTL"><strong>إذا حدث لديك أي من التأثيرات الجانبية التالية توقف عن تناول الدواء وإطلب العناية الطبية على الفور: </strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية بما في ذلك طفح جلدي (التكرار غير شائع).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر- لا تستخدم النترات ولكن اطلب المساعدة الطبية الفورية (التكرار غير شائع).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يحدث لديك إنتصاب لفترة طويلة وقد يكون مؤلما بعد تناول تادالافيل (التكرار نادر). إذا حدث لديك ذلك وبقي لديك لمدة 4 ساعات بشكل مستمر يجب التحدث مع طبيبك على الفور.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان مفاجئ للرؤية (التكرار نادر)</p><p dir="RTL"><strong>تم الإبلاغ عن حدوث الأعراض الجانبية التالية: </strong></p><p dir="RTL"><strong>شائع</strong> (يحدث في 1 إلى 10 من كل 100 مريض)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع، ألم في الظهر، ألم في العضلات، ألم في الايدي او الارجل، توهج الوجه، إحتقان الأنف، عسر الهضم وإرتداد.</p><p dir="RTL"><strong>غير شائع</strong> (يحدث في 1 إلى 10 من كل 1000 مريض)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوار، ألم في المعدة، غثيان، تقيؤ، ارتداد، عدم وضوح الرؤية، ألم في العين، صعوبة في التنفس، وجود دم في البول، انتصاب مطول، الإحساس بنبض القلب، سرعة ضربات القلب، إرتفاع ضغط الدم، إنخفاض ضغط الدم، نزف الأنف، طنين في الأذنين، تورم اليدين، الساقين او الكاحلين والشعور بتعب.</p><p dir="RTL"><strong>نادر </strong>(يحدث في 1 إلى 10 من كل 10000 مريض)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إغماء، نوبات وفقدان مؤقت للذاكرة، تورم في الجفون، إحمرار العينين، ضعف مفاجئ أو فقدان كامل للسمع وشرى (بقع حمراء على سطح الجلد تسبب الحكة)، نزيف من القضيب، وجود دم في السائل المنوي وزيادة التعرق.</p><p dir="RTL">تم الإبلاغ عن حدوث نوبة قلبية وسكتة دماغية بشكل نادر في الرجال الذين يتناولون تادالافيل. معظم هؤلاء الرجال يعانون من مشاكل في القلب قبل تناول هذا الدواء.</p><p dir="RTL">نادر ما تم الإبلاغ عن حدوث ضعف أو فقدان جزئي، مؤقت أو دائم للرؤيا في احدى او كلا العينين.</p><p dir="RTL">كما تم الإبلاغ عن حدوث الأعراض الجانبية الإضافية التالية بشكل نادر في الرجال الذين تناولوا تادالافيل. والتي تشمل:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع نصفي، تورم في الوجه، تفاعلات حساسية خطيرة قد تسبب تورم في الوجه أو الحلق، طفح جلدي خطير، بعض الإضطرابات التي تؤثر على تدفق الدم إلى العيون، عدم إنتظام ضربات القلب، ذبحة صدرية وموت قلبي مفاجئ.</p><p dir="RTL">قد تم الإبلاغ عن حدوث دوار وإسهال بشكل أكثر تكرارا في الرجال الذين تزيد أعمارهم عن 75 سنة ويتناولون تادالافيل.</p><p dir="RTL"><strong>إذا حدث لديك أي عرض جانبي، تحدث إلى طبيبك أو الصيدلي. يشمل ذلك أي أعراض جانبية محتملة غير المدرجة في هذه النشرة. </strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ بعيدا عن متناول ايدي الاطفال.</p><p dir="RTL">لا تستخدم <strong>تايرا</strong> بعد تاريخ الانتهاء المذكور على العبوة الخارجية. يدل تاريخ الانتهاء على اخر يوم في الشهر المذكور.</p><p dir="RTL">يحفظ في عبوته الأصلية دون 30 درجة مئوية.</p><p dir="RTL">يجب عدم التخلص من الأدوية في المياه العادمة أو النفايات المنزلية. إسأل الصيدلي حول الطريقة السليمة للتخلص من الأدوية التي لم تعد بحاجة إليها. سيساعد هذا في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>تايرا</strong> أقراص مغلفة: يحتوي كل قرص على 10 او 20 ملغم من تادالافيل.</p><p dir="RTL">المكونات الأخرى: لاكتوز, كروس كارميلوس صوديوم, ملح الصوديوم للوريل السلفات, هيبروميلوز, سيليلوز دقيق البلورية, ستيارات الماغنيسيوم, لون أصفر (E172), ثلاثي الأسيتين, ثاني أكسيد التيتانيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>تايرا 10 ملغم </strong>هي أقراص مغلفة لونها أصفر لوزية الشكل، مرمزة بالرمز C163 على جهة واحدة، وغير مرمزة على الجهة الأخرى.<strong> </strong></p><p dir="RTL"><strong>تايرا</strong> 20 ملغم أقراص مغلفة لونها أصفر لوزية الشكل محدبة الوجهين مرمزة بالرمز C112 على جهة واحدة فارغة من الجهة الأخرى.</p><p>تتوافر أقراص <strong>تايرا</strong> المغلفة في عبوات سعة كل منها 4 أقراص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شركة دار الدواء للتنمية والإستثمار المساهمة المحدودة (ناعور &ndash; الأردن)</p><p dir="RTL">هاتف: 132 27 57 (6 962 +)</p><p dir="RTL">فاكس: 776 27 57 (6 962 +)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            12/2017
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tyra® 10 mg film-coated tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 10 mg tadalafil.
Excipient with known effect: Each film coated tablet contains 117.250 mg of lactose
monohydrate.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
Tyra® 10 mg film coated tablets are yellow almond shape film coated tablet coded (C163) in one side, plain on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>4.1 Therapeutic indications<br />Treatment of erectile dysfunction in adult males.<br />In order for tadalafil to be effective for the treatment of erectile dysfunction, sexual<br />stimulation is required.<br />Tyra&reg; is not indicated for use by women.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />Erectile dysfunction in adult Men<br />In general, the recommended dose is 10 mg taken prior to anticipated sexual activity and with<br />or without food.<br />In those patients in whom tadalafil 10 mg does not produce an adequate effect, 20 mg might<br />be tried. It may be taken at least 30 minutes prior to sexual activity.<br />The maximum dose frequency is once per day.<br />Tadalafil 10 and 20 mg is intended for use prior to anticipated sexual activity and it is not<br />recommended for continuous daily use.<br />In patients who anticipate a frequent use of tadalafil (i.e., at least twice weekly) a once daily<br />regimen with the lowest doses of tadalafil might be considered suitable, based on patient<br />choice and the physician&#39;s judgement.<br />In these patients, the recommended dose is 5mg taken once a day at approximately the same<br />time of day. The dose may be decreased to 2.5mg tadalafil once a day based on individual<br />tolerability.<br />The appropriateness of continued use of the daily regimen should be reassessed periodically.<br />Special Populations<br />Elderly Men<br />Dose adjustments are not required in elderly patients.<br />Men with Renal Impairment<br />Dose adjustments are not required in patients with mild to moderate renal impairment. For<br />patients with severe renal impairment, 10 mg is the maximum recommended dose.<br />Once-a-day dosing of 2.5 or 5 mg tadalafil is not recommended in patients with severe renal<br />impairment.<br />Men with Hepatic Impairment<br />For the treatment of erectile dysfunction using on-demand tadalafil the recommended dose of<br />tadalafil is 10 mg taken prior to anticipated sexual activity and with or without food. There is<br />limited clinical data on the safety of tadalafil in patients with severe hepatic impairment<br />(Child-Pugh class C); if prescribed, a careful individual benefit/risk evaluation should be<br />undertaken by the prescribing physician. There are no available data about the administration<br />of doses higher than 10mg of tadalafil to patients with hepatic impairment.<br />Once-a-day dosing of tadalafil has not been evaluated in patients with hepatic impairment;<br />therefore, if prescribed, a careful individual benefit/risk evaluation should be undertaken by<br />the prescribing physician.<br />Men with Diabetes<br />Dose adjustments are not required in diabetic patients.<br />Paediatric population<br />There is no relevant use of tadalafil in the paediatric population with regard to the treatment<br />of erectile dysfunction.<br />Method of administration<br />Tyra&reg; 10 mg film-coated tablet is for oral use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
In clinical studies, tadalafil was shown to augment the hypotensive effects of nitrates. This is
thought to result from the combined effects of nitrates and tadalafil on the nitric oxide/cGMP
pathway. Therefore, administration of Tyra® to patients who are using any form of organic
nitrate is contraindicated.
Tyra®must not be used in men with cardiac disease for whom sexual activity is inadvisable.
Physicians should consider the potential cardiac risk of sexual activity in patients with preexisting
cardiovascular disease.
The following groups of patients with cardiovascular disease were not included in clinical
trials and the use of tadalafil is therefore contraindicated:
- patients with myocardial infarction within the last 90 days,
- patients with unstable angina or angina occurring during sexual intercourse,
- patients with New York Heart Association Class 2 or greater heart failure in the last 6
months,
- patients with uncontrolled arrhythmias, hypotension (<90/50 mm Hg), or uncontrolled
hypertension,
- patients with a stroke within the last 6 months.
Tadalafil is contraindicated in patients who have loss of vision in one eye because of nonarteritic
anterior ischaemic optic neuropathy (NAION), regardless of whether this episode
was in connection or not with previous PDE5 inhibitor exposure.
The co-administration of PDE5 inhibitors, including tadalafil, with guanylate cyclase
stimulators, such as riociguat, is contraindicated as it may potentially lead to symptomatic
hypotension.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Before treatment with Tyra&reg;<br />A medical history and physical examination should be undertaken to diagnose erectile<br />dysfunction and determine potential underlying causes, before pharmacological treatment is<br />considered.<br />Prior to initiating any treatment for erectile dysfunction, physicians should consider the<br />cardiovascular status of their patients, since there is a degree of cardiac risk associated with<br />sexual activity. Tadalafil has vasodilator properties, resulting in mild and transient decreases<br />in blood pressure and as such potentiates the hypotensive effect of nitrates.<br />The evaluation of erectile dysfunction should include a determination of potential underlying<br />causes and the identification of appropriate treatment following an appropriate medical<br />assessment. It is not known if tadalafil is effective in patients who have undergone pelvic<br />surgery or radical non-nerve-sparing prostatectomy.<br />Cardiovascular<br />Serious cardiovascular events, including myocardial infarction, sudden cardiac death,<br />unstable angina pectoris, ventricular arrhythmia, stroke, transient ischaemic attacks, chest<br />pain, palpitations and tachycardia, have been reported either post marketing and/or in clinical<br />trials. Most of the patients in whom these events have been reported had pre-existing<br />cardiovascular risk factors. However, it is not possible to definitively determine whether<br />these events are related directly to these risk factors, to tadalafil, to sexual activity, or to a<br />combination of these or other factors.<br />Tadalafil 2.5 mg and 5 mg - In patients receiving concomitant antihypertensive medicinal<br />products, tadalafil may induce a blood pressure decrease. When initiating daily treatment<br />with tadalafil, appropriate clinical considerations should be given to a possible dose<br />adjustment of the antihypertensive therapy.<br />In patients who are taking alpha1 blockers, concomitant administration of tadalafil may lead<br />to symptomatic hypotension in some patients. The combination of tadalafil and doxazosin is<br />not recommended.<br />Vision<br />Visual defects and cases of NAION have been reported in connection with the intake of<br />tadalafil and other PDE5 inhibitors. Analyses of observational data suggest an increased risk<br />of acute NAION in men with erectile dysfunction following exposure to tadalafil or other<br />PDE5 inhibitors. As this may be relevant for all patients exposed to tadalafil, the patient<br />should be advised that in case of sudden visual defect, he should stop taking tadalafil and<br />consult a physician immediately.<br />Decreased or sudden hearing loss<br />Cases of sudden hearing loss have been reported after the use of tadalafil. Although other risk<br />factors were present in some cases (such as age, diabetes, hypertension and previous hearing<br />loss history) patients should be advised to stop taking tadalafil and seek prompt medical<br />attention in the event of sudden decrease or loss of hearing.<br />Renal and hepatic impairment (tadalafil 2.5 mg and 5 mg)<br />Due to increased tadalafil exposure (AUC), limited clinical experience and the lack of ability<br />to influence clearance by dialysis, once-a-day dosing of tadalafil is not recommended in<br />patients with severe renal impairment.<br />There is limited clinical data on the safety of single-dose administration of tadalafil in<br />patients with severe hepatic insufficiency (Child-Pugh Class C). Once-a-day administration<br />has not been evaluated in patients with hepatic insufficiency. If Tyra&reg; is prescribed, a careful<br />individual benefit/risk evaluation should be undertaken by the prescribing physician.<br />Hepatic impairment (tadalafil 10 mg and 20 mg)<br />There is limited clinical data on the safety of single-dose administration of tadalafil in<br />patients with severe hepatic insufficiency (Child-Pugh Class C). If Tyra&reg; is prescribed, a<br />careful individual benefit/risk evaluation should be undertaken by the prescribing physician.<br />Priapism and anatomical deformation of the penis<br />Patients who experience erections lasting 4 hours or more should be instructed to seek<br />immediate medical assistance. If priapism is not treated immediately, penile tissue damage<br />and permanent loss of potency may result.<br />Tadalafil, should be used with caution in patients with anatomical deformation of the penis<br />(such as angulation, cavernosal fibrosis, or Peyronie&#39;s disease) or in patients who have<br />conditions which may predispose them to priapism (such as sickle cell anaemia, multiple<br />myeloma or leukaemia).<br />Use with CYP3A4 inhibitors<br />Caution should be exercised when prescribing tadalafil to patients using potent CYP3A4<br />inhibitors (ritonavir, saquinavir, ketoconazole, itraconazole, and erythromycin), as increased<br />tadalafil exposure (AUC) has been observed if the medicinal products are combined.<br />Tyra&reg; and other treatments for erectile dysfunction<br />The safety and efficacy of combinations of tadalafil and other PDE5 inhibitors or other<br />treatments for erectile dysfunction have not been studied. The patients should be informed<br />not to take tadalafil in such combinations.<br />Lactose<br />Tyra&reg; contains lactose. Patients with rare hereditary problems of galactose intolerance, the<br />Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal<br />product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interaction studies were conducted with 10 mg and/or 20 mg tadalafil, as indicated below.<br />With regard to those interaction studies where only the 10 mg tadalafil dose was used,<br />clinically relevant interactions at higher doses cannot be completely ruled out.<br />Effects of Other Substances on Tadalafil<br />Cytochrome P450 inhibitors<br />Tadalafil is principally metabolised by CYP3A4. A selective inhibitor of CYP3A4,<br />ketoconazole (200 mg daily), increased tadalafil (10 mg) exposure (AUC) 2-fold and Cmax by<br />15%, relative to the AUC and Cmax values for tadalafil alone. Ketoconazole (400 mg daily)<br />increased tadalafil (20 mg) exposure (AUC) 4-fold and Cmax by 22%. Ritonavir, a protease<br />inhibitor (200 mg twice daily), which is an inhibitor of CYP3A4, CYP2C9, CYP2C19, and<br />CYP2D6, increased tadalafil (20 mg) exposure (AUC) 2-fold with no change in Cmax.<br />Although specific interactions have not been studied, other protease inhibitors, such as<br />saquinavir, and other CYP3A4 inhibitors, such as erythromycin, clarithromycin, itraconazole,<br />and grapefruit juice, should be co-administered with caution, as they would be expected to<br />increase plasma concentrations of tadalafil. Consequently, the incidence of the adverse<br />reactions listed in section 4.8 might be increased.<br />Transporters<br />The role of transporters (for example, p-glycoprotein) in the disposition of tadalafil is not<br />known. Therefore, there is the potential of drug interactions mediated by inhibition of<br />transporters.<br />Cytochrome P450 inducers<br />A CYP3A4 inducer, rifampicin, reduced tadalafil AUC by 88%, relative to the AUC values<br />for tadalafil alone (10 mg). This reduced exposure can be anticipated to decrease the efficacy<br />of tadalafil; the magnitude of decreased efficacy is unknown. Other inducers of CYP3A4,<br />such as phenobarbital, phenytoin, and carbamazepine, may also decrease plasma<br />concentrations of tadalafil.<br />Effects of Tadalafil on Other Medicinal Products<br />Nitrates<br />In clinical studies, tadalafil (5, 10 and 20 mg) was shown to augment the hypotensive effects<br />of nitrates. Therefore, administration of tadalafil to patients who are using any form of<br />organic nitrate is contraindicated. Based on the results of a clinical study in which 150<br />subjects receiving daily doses of tadalafil 20 mg for 7 days and 0.4 mg sublingual<br />nitroglycerin at various times, this interaction lasted for more than 24 hours and was no<br />longer detectable when 48 hours had elapsed after the last tadalafil dose. Thus, in a patient<br />prescribed any dose of tadalafil (2.5 mg- 20 mg), where nitrate administration is deemed<br />medically necessary in a life-threatening situation, at least 48 hours should have elapsed after<br />the last dose of tadalafil before nitrate administration is considered. In such circumstances,<br />nitrates should only be administered under close medical supervision with appropriate<br />haemodynamic monitoring.<br />Anti-hypertensives (including calcium channel blockers)<br />The co-administration of doxazosin (4 and 8 mg daily) and tadalafil (5 mg daily dose and 20<br />mg as a single dose) increases the blood pressure-lowering effect of this alpha-blocker in a<br />significant manner. This effect lasts at least twelve hours and may be symptomatic, including<br />syncope. Therefore, this combination is not recommended.<br />In interaction studies performed in a limited number of healthy volunteers, these effects were<br />not reported with alfuzosin or tamsulosin. However, caution should be exercised when using<br />tadalafil in patients treated with any alpha-blockers, and notably in the elderly. Treatments<br />should be initiated at minimal dosage and progressively adjusted.<br />In clinical pharmacology studies, the potential for tadalafil to augment the hypotensive<br />effects of antihypertensive medicinal products was examined. Major classes of<br />antihypertensive medicinal products were studied, including calcium-channel blockers<br />(amlodipine), angiotensin converting enzyme (ACE) inhibitors (enalapril), beta-adrenergic<br />receptor blockers (metoprolol), thiazide diuretics (bendrofluazide), and angiotensin II<br />receptor blockers (various types and doses, alone or in combination with thiazides, calciumchannel<br />blockers, beta-blockers, and/or alpha-blockers). Tadalafil (10 mg, except for studies<br />with angiotensin II receptor blockers and amlodipine in which a 20 mg dose was applied) had<br />no clinically significant interaction with any of these classes. In another clinical<br />pharmacology study, tadalafil (20 mg) was studied in combination with up to 4 classes of<br />antihypertensives. In subjects taking multiple antihypertensives, the ambulatory-bloodpressure<br />changes appeared to relate to the degree of blood pressure control. In this regard,<br />study subjects whose blood pressure was well controlled, the reduction was minimal and<br />similar to that seen in healthy subjects. In study subjects whose blood pressure was not<br />controlled, the reduction was greater, although this reduction was not associated with<br />hypotensive symptoms in the majority of subjects. In patients receiving concomitant<br />antihypertensive medicinal products, tadalafil 20 mg may induce a blood pressure decrease,<br />which (with the exception of alpha-blockers - see above) is, in general, minor and not likely<br />to be clinically relevant. Analysis of Phase 3 clinical trial data showed no difference in<br />adverse events in patients taking tadalafil with or without antihypertensive medicinal<br />products. However, appropriate clinical advice should be given to patients regarding a<br />possible decrease in blood pressure when they are treated with antihypertensive medicinal<br />products.<br />Riociguat<br />Preclinical studies showed an additive systemic blood pressure lowering effect when PDE5<br />inhibitors were combined with riociguat. In clinical studies, riociguat has been shown to<br />augment the hypotensive effects of PDE5 inhibitors. There was no evidence of favourable<br />clinical effect of the combination in the population studied. Concomitant use of riociguat<br />with PDE5 inhibitors, including tadalafil, is contraindicated.<br />5- alpha reductase inhibitors<br />In a clinical trial that compared tadalafil 5 mg coadministered with finasteride 5 mg to<br />placebo plus finasteride 5 mg in the relief of BPH symptoms, no new adverse reactions were<br />identified. However, as a formal drug-drug interaction study evaluating the effects of<br />tadalafil and 5-alpha reductase inhibitors (5-ARIs) has not been performed, caution should be<br />exercised when tadalafil is co-administered with 5-ARIs.<br />CYP1A2 substrates (e.g. theophylline)<br />When tadalafil 10 mg was administered with theophylline (a non-selective phosphodiesterase<br />inhibitor) in a clinical pharmacology study, there was no pharmacokinetic interaction. The<br />only pharmacodynamic effect was a small (3.5 bpm) increase in heart rate. Although this<br />effect is minor and was of no clinical significance in this study, it should be considered when<br />co-administering these medicinal products.<br />Ethinylestradiol and terbutaline<br />Tadalafil has been demonstrated to produce an increase in the oral bioavailability of<br />ethinylestradiol; a similar increase may be expected with oral administration of terbutaline,<br />although the clinical consequence of this is uncertain.<br />Alcohol<br />Alcohol concentrations (mean maximum blood concentration 0.08%) were not affected by<br />co-administration with tadalafil (10 mg or 20 mg). In addition, no changes in tadalafil<br />concentrations were seen 3 hours after co-administration with alcohol. Alcohol was<br />administered in a manner to maximise the rate of alcohol absorption (overnight fast with no<br />food until 2 hours after alcohol). Tadalafil (20 mg) did not augment the mean blood pressure<br />decrease produced by alcohol (0.7 g/kg or approximately 180 ml of 40% alcohol [vodka] in<br />an 80 kg male) but, in some subjects, postural dizziness and orthostatic hypotension were<br />observed. When tadalafil was administered with lower doses of alcohol (0.6 g/kg),<br />hypotension was not observed and dizziness occurred with similar frequency to alcohol<br />alone. The effect of alcohol on cognitive function was not augmented by tadalafil (10 mg).<br />Cytochrome P450 metabolised medicinal products<br />Tadalafil is not expected to cause clinically significant inhibition or induction of the<br />clearance of medicinal products metabolised by CYP450 isoforms. Studies have confirmed<br />that tadalafil does not inhibit or induce CYP450 isoforms, including CYP3A4, CYP1A2,<br />CYP2D6, CYP2E1, CYP2C9 and CYP2C19.<br />CYP2C9 substrates (e.g. R-warfarin)<br />Tadalafil (10 mg and 20 mg) had no clinically significant effect on exposure (AUC) to Swarfarin<br />or R-warfarin (CYP2C9 substrate), nor did tadalafil affect changes in prothrombin<br />time induced by warfarin.<br />Aspirin<br />Tadalafil (10 mg and 20 mg) did not potentiate the increase in bleeding time caused by<br />acetylsalicylic acid.<br />Antidiabetic medicinal products<br />Specific interaction studies with antidiabetic medicinal products were not conducted.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tyra&reg; is not indicated for use by women.<br />Pregnancy<br />Pregnancy Category: B<br />There are limited data from the use of tadalafil in pregnant women. Animal studies do not<br />indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal<br />development, parturition or postnatal development. As a precautionary measure, it is<br />preferable to avoid the use of tadalafil during pregnancy.<br />Breastfeeding<br />Available pharmacodynamic/toxicological data in animals have shown excretion of tadalafil<br />in milk. A risk to the suckling child cannot be excluded. Tadalafil should not be used during<br />breast feeding.<br />Fertility<br />Effects were seen in dogs that might indicate impairment of fertility. Two subsequent clinical<br />studies suggest that this effect is unlikely in humans, although a decrease in sperm<br />concentration was seen in some men.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tadalafil has negligible influence on the ability to drive or use machines. Although the<br />frequency of reports of dizziness in placebo and tadalafil arms in clinical trials was similar,<br />patients should be aware of how they react to tadalafil before driving or using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile<br />The most commonly reported adverse reactions in patients taking tadalafil for the treatment<br />of erectile dysfunction were headache, dyspepsia, back pain and myalgia, in which the<br />incidences increase with increasing dose of tadalafil. The adverse reactions reported were<br />transient, and generally mild or moderate. The majority of headaches reported with tadalafil<br />once-a-day dosing are experienced within the first 10 to 30 days of starting treatment.<br />Tabulated summary of adverse reactions<br />The table below lists the adverse reactions observed from spontaneous reporting and in<br />placebo-controlled clinical trials (comprising a total of 8022 patients on tadalafil and 4422<br />patients on placebo) for on-demand and once-a-day treatment of erectile dysfunction.<br />Frequency convention: Very common (&ge;1/10), Common (&ge;1/100 to &lt;1/10), Uncommon<br />(&ge;1/1,000 to &lt;1/100), Rare (&ge;1/10,000 to &lt;1/1,000), Very Rare (&lt;1/10,000) and Not known<br />(cannot be estimated from the available data).</p><table border="1" cellspacing="0" cellpadding="0" style="width:626px"><tbody><tr><td style="vertical-align:top"><p><strong>Very common</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Immune system disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hypersensitivity reactions</p></td><td style="vertical-align:top"><p>Angioedema<sup>2</sup></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Nervous system disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>Stroke<sup>1 </sup>(including haemorrhagic events), Syncope, Transient ischaemic attacks<sup>1</sup>, Migraine<sup>2</sup>, Seizures<sup>2</sup>, Transient amnesia</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Eye disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Blurred vision, Sensations described as eye pain</p></td><td style="vertical-align:top"><p>Visual field defect, Swelling of eyelids, Conjunctival hyperaemia, Non-arteritic anterior ischaemic optic neuropathy (NAION)<sup>2</sup>, Retinal vascular occlusion<sup>2</sup></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Ear and labyrinth disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Tinnitus</p></td><td style="vertical-align:top"><p>Sudden hearing loss</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Cardiac disorders<sup>1</sup></em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Tachycardia, Palpitations</p></td><td style="vertical-align:top"><p>Myocardial infarction, Unstable angina pectoris<sup>2</sup>, Ventricular arrhythmia<sup>2</sup></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Vascular disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Flushing</p></td><td style="vertical-align:top"><p>Hypotension<sup>3</sup>, Hypertension</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Respiratory, thoracic and mediastinal disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Nasal congestion</p></td><td style="vertical-align:top"><p>Dyspnoea, Epistaxis</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Gastrointestinal disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Dyspepsia</p></td><td style="vertical-align:top"><p>Abdominal pain, Vomiting, Nausea, Gastro-oesophageal reflux</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Skin and subcutaneous tissue disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Urticaria, Stevens-Johnson syndrome<sup>2</sup>, Exfoliative dermatitis<sup>2</sup>, Hyperhydrosis (sweating)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Musculoskeletal, connective tissue and bone disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Back pain, Myalgia, Pain in extremity</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Renal and urinary disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Haematuria</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Reproductive system and breast disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Prolonged erections</p></td><td style="vertical-align:top"><p>Priapism, Penile haemorrhage, Haematospermia</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>General disorders and administration site conditions</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Chest pain<sup>1, </sup>Peripheral oedema, Fatigue</p></td><td style="vertical-align:top"><p>Facial oedema<sup>2</sup>, Sudden cardiac death<sup>1,2</sup></p></td></tr></tbody></table><p>(1) Most of the patients had pre-existing cardiovascular risk factors.</p><p>(2) Postmarketing surveillance reported adverse reactions not observed in placebo-controlled clinical trials.</p><p>(3) More commonly reported when tadalafil is given to patients who are already taking antihypertensive medicinal products.</p><p><u>Description of selected adverse reactions</u></p><p>A slightly higher incidence of ECG abnormalities, primarily sinus bradycardia, has been<br />reported in patients treated with tadalafil once a day as compared with placebo. Most of these<br />ECG abnormalities were not associated with adverse reactions.<br />Other special populations<br />Data in patients over 65 years of age receiving tadalafil in clinical trials, either for the<br />treatment of erectile dysfunction or the treatment of benign prostatic hyperplasia (5 mg), are<br />limited. In clinical trials with tadalafil taken on demand for the treatment of erectile<br />dysfunction, diarrhoea was reported more frequently in patients over 65 years of age. In<br />clinical trials with tadalafil 5 mg taken once a day for the treatment of benign prostatic<br />hyperplasia, dizziness and diarrhoea were reported more frequently in patients over 75 years<br />of age.<br />To report any side effects:<br />&bull; National Pharmacovigilance and Drug Safety Centre (NPC)<br />&minus; Fax: + 966 112057662<br />&minus; Call NPC at + 966 112038222, Exts: 2317-2356-2353-2354-2334-2340<br />&minus; Toll free phone: 8002490000<br />&minus; E-mail: npc.drug@sfda.gov.sa<br />&minus; Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Single doses of up to 500 mg have been given to healthy subjects, and multiple daily doses<br />up to 100 mg have been given to patients. Adverse events were similar to those seen at lower<br />doses.<br />In cases of overdose, standard supportive measures should be adopted, as required.<br />Haemodialysis contributes negligibly to tadalafil elimination.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Urologicals, Drugs used in erectile dysfunction. ATC code:<br />G04BE08.<br />Mechanism of action<br />Tadalafil is a selective, reversible inhibitor of cyclic guanosine monophosphate (cGMP)-<br />specific phosphodiesterase type 5 (PDE5). When sexual stimulation causes the local release<br />of nitric oxide, inhibition of PDE5 by tadalafil produces increased levels of cGMP in the<br />corpus cavernosum. This results in smooth muscle relaxation and inflow of blood into the<br />penile tissues, thereby producing an erection. Tadalafil has no effect in the treatment of<br />erectile dysfunction in the absence of sexual stimulation.<br />Pharmacodynamic effects<br />Studies in vitro have shown that tadalafil is a selective inhibitor of PDE5. PDE5 is an<br />enzyme found in corpus cavernosum smooth muscle, vascular and visceral smooth muscle,<br />skeletal muscle, platelets, kidney, lung, and cerebellum. The effect of tadalafil is more potent<br />on PDE5 than on other phosphodiesterases. Tadalafil is &gt;10,000-fold more potent for PDE5<br />than for PDE1, PDE2, and PDE4 enzymes which are found in the heart, brain, blood vessels,<br />liver, and other organs. Tadalafil is &gt;10,000-fold more potent for PDE5 than for PDE3, an<br />enzyme found in the heart and blood vessels. This selectivity for PDE5 over PDE3 is<br />important because PDE3 is an enzyme involved in cardiac contractility. Additionally,<br />tadalafil is approximately 700-fold more potent for PDE5 than for PDE6, an enzyme which is<br />found in the retina and is responsible for phototransduction. Tadalafil is also &gt;10,000-fold<br />more potent for PDE5 than for PDE7 through PDE10.<br />Clinical efficacy and safety<br />Tadalafil administered to healthy subjects produced no significant difference compared to<br />placebo in supine systolic and diastolic blood pressure (mean maximal decrease of<br />1.6/0.8mmHg, respectively), in standing systolic and diastolic blood pressure (mean maximal<br />decrease of 0.2/4.6mmHg, respectively), and no significant change in heart rate.<br />In a study to assess the effects of tadalafil on vision, no impairment of colour discrimination<br />(blue/green) was detected using the Farnsworth-Munsell 100-hue test. This finding is<br />consistent with the low affinity of tadalafil for PDE6 compared to PDE5. Across all clinical<br />studies, reports of changes in colour vision were rare (&lt;0.1%).<br />Three studies were conducted in men to assess the potential effect on spermatogenesis of<br />tadalafil 10mg (one 6-month study) and 20mg (one 6-month and one 9-month study)<br />administered daily. In two of these studies decreases were observed in sperm count and<br />concentration related to tadalafil treatment of unlikely clinical relevance. These effects were<br />not associated with changes in other parameters, such as motility, morphology, and FSH.<br />Erectile dysfunction<br />Three clinical studies were conducted in 1054 patients in an at-home setting to define the<br />period of responsiveness to tadalafil on demand. Tadalafil demonstrated statistically<br />significant improvement in erectile function and the ability to have successful sexual<br />intercourse up to 36 hours following dosing, as well as patients&#39; ability to attain and maintain<br />erections for successful intercourse compared to placebo as early as 16 minutes following<br />dosing.<br />In a 12-week study performed in 186 patients (142 tadalafil, 44 placebo) with erectile<br />dysfunction secondary to spinal cord injury, tadalafil significantly improved the erectile<br />function leading to a mean per-subject proportion of successful attempts in patients treated<br />with tadalafil 10 or 20 mg (flexible-dose, on demand) of 48% as compared to 17% with<br />placebo.<br />Tadalafil at doses of 2 to 100mg has been evaluated in 16 clinical studies involving 3250<br />patients, including patients with erectile dysfunction of various severities (mild, moderate,<br />severe), etiologies, ages (range 21-86 years), and ethnicities. Most patients reported erectile<br />dysfunction of at least 1 year in duration. In the primary efficacy studies of general<br />populations, 81% of patients reported that tadalafil improved their erections as compared to<br />35% with placebo. Also, patients with erectile dysfunction in all severity categories reported<br />improved erections whilst taking tadalafil (86%, 83%, and 72% for mild, moderate, and<br />severe, respectively, as compared to 45%, 42%, and 19% with placebo). In the primary<br />efficacy studies, 75% of intercourse attempts were successful in tadalafil -treated patients as<br />compared to 32% with placebo.<br />For once-a-day evaluation of tadalafil at doses of 2.5, 5, and 10 mg 3 clinical studies were<br />initially conducted involving 853 patients of various ages (range 21-82 years) and ethnicities,<br />with erectile dysfunction of various severities (mild, moderate, severe) and etiologies. In the<br />two primary efficacy studies of general populations, the mean per-subject proportion of<br />successful intercourse attempts were 57 and 67% on tadalafil 5mg, 50% on tadalafil 2.5mg as<br />compared to 31 and 37% with placebo. In the study in patients with erectile dysfunction<br />secondary to diabetes, the mean per-subject proportion of successful attempts were 41 and<br />46% on tadalafil 5mg and 2.5mg, respectively, as compared to 28% with placebo. Most<br />patients in these three studies were responders to previous on-demand treatment with PDE5<br />inhibitors. In a subsequent study, 217 patients who were treatment-naive to PDE5 inhibitors<br />were randomised to tadalafil 5mg once a day vs. placebo. The mean per-subject proportion of<br />successful sexual intercourse attempts was 68% for tadalafil patients compared to 52% for<br />patients on placebo.<br />Paediatric population<br />A single study has been performed in paediatric patients with Duchenne Muscular Dystrophy<br />(DMD) in which no evidence of efficacy was seen. The randomised, double&ndash;blind, placebo&ndash;<br />controlled, parallel, 3&ndash;arm study of tadalafil was conducted in 331 boys aged 7&ndash;14 years with<br />DMD receiving concurrent corticosteroid therapy. The study included a 48&ndash;week doubleblind<br />period where patients were randomised to tadalafil 0.3 mg/kg, tadalafil 0.6 mg/kg, or<br />placebo daily. Tadalafil did not show efficacy in slowing the decline in ambulation as<br />measured by the primary 6 minute walk distance (6MWD) endpoint: least squares (LS) mean<br />change in 6MWD at 48 weeks was &ndash;51.0 meters (m) in the placebo group, compared with &ndash;<br />64.7 m in the tadalafil 0.3 mg/kg group (p = 0.307) and &ndash;59.1 m in the tadalafil 0.6 mg/kg<br />group (p = 0.538). In addition, there was no evidence of efficacy from any of the secondary<br />analyses performed in this study. The overall safety results from this study were generally<br />consistent with the known safety profile of tadalafil and with adverse events (AEs) expected<br />in a paediatric DMD population receiving corticosteroids.<br />The European Medicines Agency has waived the obligation to submit the results of studies in<br />all subsets of the paediatric population in the treatment of the erectile dysfunction. See<br />section 4.2 for information on paediatric use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />Tadalafil is readily absorbed after oral administration and the mean maximum observed<br />plasma concentration (Cmax) is achieved at a median time of 2 hours after dosing. Absolute<br />bioavailability of tadalafil following oral dosing has not been determined.<br />The rate and extent of absorption of tadalafil are not influenced by food, thus tadalafil may<br />be taken with or without food. The time of dosing (morning versus evening) had no clinically<br />relevant effects on the rate and extent of absorption.<br />Distribution<br />The mean volume of distribution is approximately 63 l, indicating that tadalafil is distributed<br />into tissues. At therapeutic concentrations, 94% of tadalafil in plasma is bound to proteins.<br />Protein binding is not affected by impaired renal function.<br />Less than 0.0005% of the administered dose appeared in the semen of healthy subjects.<br />Biotransformation<br />Tadalafil is predominantly metabolised by the cytochrome P450 (CYP) 3A4 isoform. The<br />major circulating metabolite is the methylcatechol glucuronide. This metabolite is at least<br />13,000-fold less potent than tadalafil for PDE5. Consequently, it is not expected to be<br />clinically active at observed metabolite concentrations.<br />Elimination<br />The mean oral clearance for tadalafil is 2.5 l/h and the mean half-life is 17.5 hours in healthy<br />subjects.<br />Tadalafil is excreted predominantly as inactive metabolites, mainly in the faeces<br />(approximately 61% of the dose) and to a lesser extent in the urine (approximately 36% of<br />the dose).<br />Linearity/Non-Linearity<br />Tadalafil pharmacokinetics in healthy subjects are linear with respect to time and dose. Over<br />a dose range of 2.5 to 20 mg, exposure (AUC) increases proportionally with dose. Steadystate<br />plasma concentrations are attained within 5 days of once daily dosing.<br />Pharmacokinetics determined with a population approach in patients with erectile<br />dysfunction are similar to pharmacokinetics in subjects without erectile dysfunction.<br />Special Populations<br />Elderly<br />Healthy elderly subjects (65 years or over) had a lower oral clearance of tadalafil, resulting in<br />25% higher exposure (AUC) relative to healthy subjects aged 19 to 45 years. This effect of<br />age is not clinically significant and does not warrant a dose adjustment.<br />Renal Insufficiency<br />In clinical pharmacology studies using single dose tadalafil (5 to 20mg), tadalafil exposure<br />(AUC) approximately doubled in subjects with mild (creatinine clearance 51 to 80 ml/min)<br />or moderate (creatinine clearance 31 to 50 ml/min) renal impairment and in subjects with<br />end-stage renal disease on dialysis. In haemodialysis patients, Cmax was 41% higher than that<br />observed in healthy subjects. Haemodialysis contributes negligibly to tadalafil elimination.<br />Hepatic Insufficiency<br />Tadalafil exposure (AUC) in subjects with mild and moderate hepatic impairment (Child-<br />Pugh class A and B) is comparable to exposure in healthy subjects when a dose of 10 mg is<br />administered. There is limited clinical data on the safety of tadalafil in patients with severe<br />hepatic insufficiency (Child-Pugh class C). If tadalafil is prescribed, a careful individual<br />benefit/risk evaluation should be undertaken by the prescribing physician. There are no<br />available data about the administration of once-a-day dosing of tadalafil to patients with<br />hepatic impairment. If tadalafil is prescribed once-a-day, a careful individual benefit/risk<br />evaluation should be undertaken by the prescribing physician. There are no available data<br />about the administration of doses higher than 10 mg of tadalafil to patients with hepatic<br />impairment.<br />Patients with Diabetes<br />Tadalafil exposure (AUC) in patients with diabetes was approximately 19% lower than the<br />AUC value for healthy subjects. This difference in exposure does not warrant a dose<br />adjustment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of<br />safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, and<br />toxicity to reproduction.<br />There was no evidence of teratogenicity, embryotoxicity, or foetotoxicity in rats or mice that<br />received up to 1000 mg/kg/day tadalafil. In a rat prenatal and postnatal development study,<br />the no observed effect dose was 30 mg/kg/day. In the pregnant rat the AUC for calculated<br />free drug at this dose was approximately 18-times the human AUC at a 20 mg dose.<br />There was no impairment of fertility in male and female rats. In dogs given tadalafil daily for<br />6 to 12 months at doses of 25 mg/kg/day (resulting in at least a 3-fold greater exposure<br />[range 3.7-18.6] than seen in humans given a single 20 mg dose) and above, there was<br />regression of the seminiferous tubular epithelium that resulted in a decrease in<br />spermatogenesis in some dogs. See also section 5.1.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose monohydrate<br />Croscarmellose sodium<br />Sodium laurilsulfate<br />Hypromellose<br />Microcrystalline cellulose<br />Magnesium stearate<br />Titanium dioxide<br />Triacetin<br />Iron oxide yellow (E172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C in the original package.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Immediate packaging&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Outer packaging<br />PVC/PVDC/Aluminum Blister&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Carton<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Leaflet</p><p>Tyra&reg; 10 mg film coated tablets are packed in aluminum blisters enclosed in a carton along<br />with a leaflet. Tyra&reg; 10 mg is available in packs of 4 tablets (4 blisters each containing 1<br />tablet).<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Medicines should not be disposed of via wastewater or household waste.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dar Al Dawa Development & Investment Co. Ltd.
P.O.Box 9364
Na’ur - Jordan
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                31/10/2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>